本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-057 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于证券事务代表辞职的公告 特此公告。 广州洁特生物过滤股份有限公司董事会 2025 年 9 月 13 日 1 广州洁特生物过滤股份有限公司（以下简称"公司"）董事会于近日收到证 券事务代表邢婉芳女士的书面辞职报告。邢婉芳女士因个人原因申请辞去公司证 券事务代表一职，辞职后将不再担任公司任何职务，辞职报告自送达董事会之日 起生效，其负责的工作已完成交接，其辞职不会影响公司相关工作的正常开展。 邢婉芳女士在担任公司证券事务代表期间，恪尽职守、勤勉尽责，在公司治 理、信息披露及规范运作等方面发挥了积极的作用，公司及董事会对邢婉芳女士 在职期间为公司发展做出的努力和贡献表示衷心感谢！ 公司董事会将根据《上海证券交易所科创板股票上市规则》等相关规定，尽 快聘任符合任职资 ...

洁特生物公告，公司董事会近日收到证券事务代表邢婉芳女士的书面辞职报告。邢婉芳女士因个人原因 申请辞去公司证券事务代表一职，辞职后将不再担任公司任何职务。其负责的工作已完成交接，辞职不 会影响公司相关工作的正常开展。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、对外投资设立产业基金概述 广州洁特生物过滤股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召 开第四届董事会第二十一次会议，审议通过了《关于拟对外投资设立产业基金的 议案》。为深化落实公司战略发展规划，加深产业资本合作，借助专业投资机构 的力量及资源优势通过股权投资进一步发掘具有产业协同效应的优质项目，助力 公司长远发展，公司与广州南粤澳洋基金管理有限公司（以下简称"南粤澳洋"）、 广州南粤基金集团有限公司（以下简称"南粤基金"）出资发起设立广州增城区 南特生物医药投资合伙企业（有限合伙）（以下简称"南特投资"），主要投资 于早、中期生物医药类项目，产业基金总出资额为人民币 5,001 万元，其中公司 作为有限合伙人认缴出资人民币 2,500 万元，占认缴出资额的 49.99%。 具体内容详见公司于 2025 年 7 月 4 日披露的《关于拟对外投资设立产业基 金的公告》（公告编号：2025-042）。 二、对外投资设立产业基金的进展情况 | 证券代码：6 ...

广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688026 证券简称：洁特生物 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 9 月 16 日 1 广州洁特生物过滤股份有限公司 2025 年第二次临时股东大会会议资料 股东大会须知 为保障广州洁特生物过滤股份有限公司全体股东的合法权益，维护股东大会 的正常秩序，保证股东大会的议事效率，确保本次股东大会如期、顺利召开，根 据《公司法》《公司章程》《股东大会议事规则》及中国证监会、上交所的有关规 定，特制定本须知。 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东（或股东代表） 的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级管理人员、 见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会场。 三、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办理 签到手续，并请按规定出示证券账户卡、身份证或法人单位证明、授权委托书等， 经验证后方可 ...

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]

2025年8月30日，洁特生物(688026.SH)发布2025年中报。 公司营业总收入为2.68亿元，较去年同报告期营业总收入增加3189.25万元，实现2年连续上涨，同比较 去年同期上涨13.50%。归母净利润为4633.86万元，较去年同报告期归母净利润增加1633.84万元，实现 2年连续上涨，同比较去年同期上涨54.46%。经营活动现金净流入为8416.94万元，在已披露的同业公司 中排名第44，较去年同报告期经营活动现金净流入增加6870.25万元，同比较去年同期上涨444.19%。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 袁建华 | 29.26% | | 2 | JET(H.K.) BIOSCIENCE CO., LIMITED | 12.50% | | 3 | 洛阳麦金顿企业管理合伙企业(有限合伙) | 1.70% | | 4 | 珠海阿巴马私募基金投资管理有限公司-阿巴马元享红利80号私募证券投资基金 | 1.42% | | 5 | 中国银行股份有限公司-嘉实领先优势混合型证券投资基金 | 1.19% | | ଚ | 广州萝岗区汇资投资管 ...

Core Insights - The company, Guangzhou Jiete Biological Filtration Co., Ltd., reported a revenue of 268 million yuan for the first half of 2025, representing a year-on-year growth of 13.50% [1] - The net profit attributable to shareholders reached 46.34 million yuan, marking a significant increase of 54.46% compared to the same period last year [1] - The growth in revenue was influenced by customers' anticipation of factory relocation and efforts to avoid Sino-U.S. trade frictions, leading to early inventory stocking [1] Group 1 - The company has actively pursued cost reduction and efficiency improvement by enhancing production automation and implementing cost management systems, resulting in better control over costs and increased price competitiveness of its products [1] - The company aims to provide comprehensive solutions for biological laboratories, with its main products including biological culture and liquid handling consumables, along with a range of related products and services [1] Group 2 - In line with the trends in the domestic life sciences and IVD industries, the company has increased its R&D investment in disposable plastic consumables for biological laboratories, focusing on market demands in cell therapy, biomedicine, and vaccine development [2] - The company has developed new products including reagent bottles, closed systems for shaking flasks, petri dishes, and centrifuge tube racks, and has filed 23 patent applications, with 15 patents granted during the reporting period [2] Group 3 - The company has established large-scale production bases in Guangzhou Huangpu and Zengcheng, featuring 65,000 square meters of GMP-grade clean production facilities [3] - With the full operation of the Zengcheng factory and the introduction of smart manufacturing workshops in 2025, the company's production capacity has significantly increased, making it one of the largest manufacturers in the domestic industry [3] - The company leverages its substantial production capacity to effectively control production costs and enhance product price competitiveness, while also establishing long-term stable partnerships with key international clients [3]

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 23rd meeting of the fourth board on August 28, 2025, to review the semi-annual evaluation report of the 2025 quality improvement and efficiency enhancement action plan [1] - For the fiscal year 2024, Jiet Biotech's revenue composition shows that consumables account for 95.02% of total revenue, while other businesses contribute 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.7 billion yuan [1]

证券日报网讯8月29日晚间，洁特生物发布公告称，公司将于2025年9月16日召开2025年第二次临时股东 大会。本次股东大会将审议《关于取消监事会、监事及修订 <公司章程> 的议案》《关于修订部分公司 治理制度的议案》等多项议案。 ...